Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider Michael Geffner sold 3,261 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $28.90, for a total value of $94,242.90. Following the transaction, the insider now owns 141,616 shares in the company, valued at approximately $4,092,702.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Immunovant Stock Down 2.1 %
Shares of NASDAQ IMVT opened at $27.17 on Friday. Immunovant, Inc. has a 1 year low of $15.90 and a 1 year high of $45.58. The business has a 50-day moving average of $32.10 and a two-hundred day moving average of $35.79.
Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings results on Monday, February 12th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Equities research analysts anticipate that Immunovant, Inc. will post -1.7 EPS for the current fiscal year.
Institutional Trading of Immunovant
Tech GIANT’s Plans to Revolutionize Crypto…
From Crypto 101 Media | Ad
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products.
If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE…
The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Claim your free seat by clicking here now.
Several institutional investors and hedge funds have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System increased its position in Immunovant by 3.0% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 15,774 shares of the company's stock valued at $606,000 after acquiring an additional 460 shares during the period. Alps Advisors Inc. raised its position in Immunovant by 0.6% during the 3rd quarter. Alps Advisors Inc. now owns 96,434 shares of the company's stock worth $3,702,000 after buying an additional 578 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Immunovant in the 4th quarter worth $27,000. CoreCap Advisors LLC increased its stake in shares of Immunovant by 11.2% during the fourth quarter. CoreCap Advisors LLC now owns 6,407 shares of the company's stock worth $270,000 after acquiring an additional 647 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Immunovant by 10.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,370 shares of the company's stock worth $437,000 after purchasing an additional 951 shares in the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on IMVT shares. Oppenheimer assumed coverage on shares of Immunovant in a report on Thursday, March 28th. They set an "outperform" rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Immunovant in a research report on Tuesday, February 20th. They issued an "overweight" rating and a $51.00 target price for the company. Wolfe Research initiated coverage on shares of Immunovant in a research note on Thursday, February 15th. They set an "outperform" rating and a $55.00 price objective for the company. The Goldman Sachs Group started coverage on Immunovant in a research report on Wednesday, March 13th. They issued a "buy" rating and a $50.00 price target for the company. Finally, Truist Financial reissued a "buy" rating and set a $48.00 price objective on shares of Immunovant in a research report on Monday, March 25th. Seventeen analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $48.00.
Read Our Latest Research Report on Immunovant
Immunovant Company Profile
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
